IGF-1 LR3 — the long-acting IGF-1 analog, explained
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of native insulin-like growth factor 1 (IGF-1) engineered with two structural modifications: a substitution of glutamate at position 3 with arginine (the "R3") and a 13-amino-acid N-terminal extension derived from porcine growth hormone (the "Long" prefix). Together these modifications dramatically reduce IGF-1 LR3's affinity for IGF-binding proteins (IGFBPs) in serum, extending the bioavailable half-life from roughly 10 minutes (native IGF-1) to approximately 20-30 hours. This primer covers the molecule, the LR3 modification's rationale, the published research applications, administration routes, and what researchers should know before working with it.
The molecule. IGF-1 LR3 is an 83-amino-acid protein (70 residues of the native IGF-1 sequence + 13 residues of N-terminal extension) with molecular weight approximately 9200 Da. Native human IGF-1 is a 70-amino-acid protein at ~7649 Da. The Glu3→Arg3 substitution and the 13-residue extension together disrupt the binding site for IGFBPs (primarily IGFBP-3, which carries ~80% of circulating IGF-1 in serum). The IGF-1 receptor (IGF-1R) binding site is preserved — IGF-1 LR3 binds IGF-1R with similar affinity to the native ligand, which is why it retains biological activity while escaping IGFBP sequestration.
Why the LR3 modification matters. Native IGF-1 in serum is ~99% bound to IGFBPs, with free/bioavailable IGF-1 tightly regulated by the IGFBP pool. This regulation makes native IGF-1 a poor experimental tool for studying receptor signaling — dosing it produces transient and variable free-IGF-1 exposure. IGF-1 LR3 escapes this regulation and provides sustained receptor engagement, which makes it the preferred tool for studying IGF-1R signaling in cell culture and in animal models where consistent receptor occupancy is needed. Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 1988;251(1):95-103 is a foundational paper on the LR3 rationale; Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-223 establishes the biological activity comparison.
Research applications. IGF-1 LR3 is used across three broad domains: (1) cell-culture work — it is a standard supplement in serum-free media for studies of cell proliferation, differentiation, and survival across many cell types; (2) in vivo rodent studies of muscle growth, tissue regeneration, and the growth-hormone / IGF-1 axis; (3) receptor-pharmacology studies where IGF-1R-specific effects need to be isolated from the IGFBP-modulated behavior of native ligand. Recombinant IGF-1 LR3 has been produced at commercial scale since the 1990s specifically because the LR3 variant is more useful than native IGF-1 for these applications.
Receptor biology. The IGF-1 receptor (IGF-1R) is a transmembrane tyrosine kinase structurally related to the insulin receptor (InsR). At high concentrations IGF-1 LR3 can cross-activate InsR (the two receptors share ~60% sequence homology in their extracellular domains), which is a relevant pharmacological consideration. Downstream signaling is via IRS-1/2 → PI3K → Akt and via Shc → Ras → MAPK, which are the mitogenic and anti-apoptotic pathways respectively. Sustained IGF-1R activation is a well-studied driver of cell proliferation — which is why IGF-1 LR3 is powerful in research contexts and why the same pathway is under investigation as a target for oncology drug development.
Administration routes and dose ranges. IGF-1 LR3 has been studied via subcutaneous injection (the dominant in vivo route), intravenous (less common, short duration studies), and intraperitoneal (rodent studies). Cell-culture work uses the peptide directly in media. Published rodent protocols use doses in the 10-100 μg/kg range administered daily over multi-week protocols. Human research data is limited — a small number of older clinical studies (primarily in the 1990s) examined native IGF-1 in growth-deficiency research, but the LR3 variant has not been through the same clinical development.
Storage, stability, and handling. Lyophilized IGF-1 LR3 is stable at 2–8 °C for extended periods when properly dried; reconstituted solutions are less stable than the smaller peptide-agonist class (tirzepatide, semaglutide). At ~9 kDa IGF-1 LR3 is a small protein rather than a peptide, and protein stability considerations apply — avoid repeated freeze-thaw cycles, avoid vigorous agitation (aggregation risk), keep pH near neutral in reconstitution buffer. The pen format Vivaprime ships addresses reconstitution and storage stability via a factory-dissolved, stability-tested solvent system. Do not freeze the pen. Protect from light.
What the COA should say. A batch-specific COA for IGF-1 LR3 should include (1) identity confirmation by HPLC-MS against the theoretical mass of approximately 9200 Da — note that for a ~9 kDa protein, mass accuracy tolerance is wider than for small peptides (typical spec ± 1 Da), (2) purity by reverse-phase HPLC and/or SDS-PAGE — for proteins of this size, SDS-PAGE is commonly used as a complementary method to HPLC, (3) endotoxin by LAL in EU/mg (important — recombinant protein production in E. coli has endotoxin as a common contaminant if not purified rigorously), (4) bioactivity by cell-proliferation assay (optional but valuable for research-grade material — confirms the protein folds correctly and retains IGF-1R activity). The production source (recombinant E. coli is the standard) should be noted on the COA.
Research-use only. Vivaprime supplies IGF-1 LR3 as research reference material for qualified researchers engaged in in-vitro laboratory work. IGF-1 LR3 has not been approved by the FDA for any therapeutic indication. It is on the WADA prohibited list for athletic use. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Sustained IGF-1R activation has known proliferative effects that are relevant for oncology research — serious readers should consider these pathway effects in experimental design. Purchasers affirm the research-use agreement at checkout.